By 2020, Chouinard’s discomfort with his ownership of the lucrative outdoor apparel brand was ramping up. While Patagonia has ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

»Der har været en periode, hvor vi skulle kalde vores produktionsfolk ind for at producere lidt ekstra eller lave nogle ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Company of China, Ltd. ("Ping An" or the "Group", HKEx: 2318 / 82318; SSE: 601318) took top spot in the Brand Finance Insurance 100 2025 ranking, for the ninth year in a row, boasting a brand value of ...

WALKING into the WeightWatchers meeting with her mum, then-eight-year-old Sarah Le Brocq was wide-eyed. It was 1990 and she ...